Adaptive Biotechnologies Corporation reiterated revenue guidance for the full year 2022. For the year, the company reiterated revenue to be in the range of $185 million to $195 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.49 USD | -2.79% | -11.87% | -28.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.78% | 529M | |
-27.66% | 9.41B | |
+26.94% | 2.9B | |
-15.73% | 2.16B | |
-20.83% | 1.7B | |
+67.18% | 1.51B | |
+26.08% | 814M | |
-4.15% | 760M | |
+3.98% | 312M | |
-24.19% | 183M |
- Stock Market
- Equities
- ADPT Stock
- News Adaptive Biotechnologies Corporation
- Adaptive Biotechnologies Corporation Reiterates Revenue Guidance for the Full Year 2022